ZENEO® Midazolam earns the orphan drug designation

Image de l'actualité
Date de parution
Contenu texte de l'actualité

The American Food and Drug Administration (FDA) has granted Orphan Drug Designation to ZENEO® Midazolam for the treatment of status epilepticus (epileptic seizure lasting longer than 5 minutes).
The orphan designation for ZENEO® Midazolam improves Crossject’s international visibility and gives impetus to its current negotiations for partnerships with pharmaceutical laboratories. 

Read more on the section "Press release".